After much hope and controversy, for the first time stem cells have proven to have the ability to cure blindness.
The news comes from a study on age-related macular degeneration (AMD) of the retina, the most common cause of blindness in individuals over the age of 50.
The Sunday Times reports that the treatment was developed by a group of British researchers, who say that in the next six to seven years the treatment will become a routine operation, which will not last more than an hour.
The treatment involves the replacement of a layer of degenerated cells with new cells created
Image via Wikipedia
The Missouri Roundtable for Life, a St. Louis area association led by conservative Ed Martin is organizing events to collect signatures for a November 2010 referendum.
The proposal, presented to the Secretary of State office, entitled “Amendment for the protection of taxpayer money”, asks to not use taxpayer money to fund abortion, human cloning, and other controversial research.
The group’s website, states that they are concerned with limiting or eliminating the effects of Amendment 2 passed in 2006 by a light majority, a law that protects research permitted by federal laws.
We have been told for almost a decade that stem cells are the future of medicine: that these tiny clumps of tissue could become a biological “repair kit”, able to regenerate or heal almost any part of the body. But amid all the prophecies of patches for damaged hearts, new nerve cells for spinal injuries or stroke victims, and insulin-producing cells for diabetics, few people predicted that it would be British-based scientists who would be leading the way in mapping out this new terrain.
Writing in The Daily Telegraph last week, Professor Steve Jones bemoaned the failure of
Sierra Fedelem may look like any other 20-month-old, but her parents are doing everything they can to make sure her life is just like that of any other healthy human being.
Stem cell research has stirred quite the controversy in the United States, and though the current administration’s recent policy reversal on the issue could open the markets to treatments and commercialization, it’s still an option unavailable for American patients, like Sierra, unless they’re willing to travel across the world.
“The first time the neurologist said, ‘No, you don’t realize it, she’s never going to be able to walk, talk and
Stem Cell Therapeutics Corp. is pleased to announce the U.S. Food and Drug Administration (FDA) has provided a verbal confirmation to remove its clinical hold placed on NTx®-265 on September 18, 2008. This will allow SCT to commence the recruitment of patients under an amended protocol using NTx®-265 for the Company’s Phase IIb clinical trial treating acute ischemic stroke.
Dr. Alan Moore, President and CEO, commented as follows:
“We are very pleased that our series of collaborative meetings with the FDA has resulted in this positive development. We are expecting to receive written notification from the FDA in the near future